Managers / Q1 2026
Aikya Investment Management Ltd
CIK 0002005403 · OCTAGON POINT, 5 CHEAPSIDE, LONDON, X0, EC2V 6AA · 442039654392
Summary
Aikya Investment Management Ltd reported $345M in U.S.-listed holdings across 4 positions for Q1 2026.
The portfolio is heavily concentrated: EPAM alone accounts for 35.8% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ADR · 64.2% · $221M
- Common Stock · 35.8% · $123M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| INFYInfosys Ltd | ADDED | +113.2K | 596.3K | −$552,279 | $8M |
| EPAMEPAM Systems Inc | ADDED | +146.8K | 910.6K | −$33M | $123M |
| HDBHDFC Bank Limited | TRIMMED | −606.2K | 4.12M | −$70M | $103M |
| Dr. Reddy's Laboratories Limited | ADDED | +661.3K | 8.00M | +$8M | $111M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | EPAMEPAM Systems Inchistory → | Common Stock | 35.76% | $123M | 910.6K |
| 2 | Dr. Reddy's Laboratories Limited | ADR | 32.14% | $111M | 8.00M |
| 3 | HDBHDFC Bank Limitedhistory → | ADR | 29.76% | $103M | 4.12M |
| 4 | INFYInfosys Ltdhistory → | ADR | 2.34% | $8M | 596.3K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $345M | 4 | May 5, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $441M | 4 | Feb 2, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $357M | 4 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $333M | 4 | Aug 5, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $270M | 4 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $240M | 3 | Feb 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $180M | 3 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $346M | 3 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $273M | 3 | May 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $224M | 3 | Jan 12, 2024 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.